Laboratory Studies Into the Pathology of Leukaemia
- Conditions
- Leukemia
- Registration Number
- NCT03233763
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
Ongoing laboratory work into the pathology of Leukaemia:
- Detailed Description
The investigators will test AML samples sent to the diagnostic laboratory from participants with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general hospitals and teaching hospitals.
Results will be returned to referring clinicians in the same way investigators currently return results for samples sent for standard tests. The service will be advertised through the Royal Marsden Website with visibility to both participants and HCPs). The investigators will also inform all the clinicians involved in the AML working party (Dr Taussig is a member of the AML working group).
In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification.
An initial comparison of 50 samples by three analysis methods will be conducted.
IDH1 and IDH2 variant discovery will first be performed using an established standard in house SOP (SOP: SMD103) for CE-SSCA
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
18 & Over Diagnosis of AML Generic Research consent given
Under 18 No generic research consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathology of Leukaemia cells 15 years Pathology of Leukaemia cells
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Haematology, the Royal Marsden NHS Foundation Trust
🇬🇧Sutton, Surrey, United Kingdom